PMID- 23455233
OWN - NLM
STAT- MEDLINE
DCOM- 20131025
LR  - 20220331
IS  - 1539-2864 (Electronic)
IS  - 0275-004X (Linking)
VI  - 33
IP  - 4
DP  - 2013 Apr
TI  - Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical 
      diagnosis and treatment.
PG  - 686-716
LID - 10.1097/IAE.0b013e3182852446 [doi]
AB  - BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy 
      affecting vision, with clinical features distinct from neovascular age-related 
      macular degeneration. Currently, no evidence-based guidelines exist for its 
      diagnosis and treatment. METHODS: A panel of experts analyzed a systematic 
      literature search on PCV together with results of the EVEREST trial, the only 
      published randomized controlled clinical trial in PCV. At a subsequent Roundtable 
      meeting, recommendations for the management of PCV were agreed based on this 
      analysis and their own expert opinion. RESULTS: Diagnosis of PCV should be based 
      on early-phase nodular hyperfluorescence from choroidal vasculature visualized 
      using indocyanine green angiography. Recommended initial treatment of juxtafoveal 
      and subfoveal PCV is either indocyanine green angiography-guided verteporfin 
      photodynamic therapy or verteporfin photodynamic therapy plus 3 x 0.5 mg 
      ranibizumab intravitreal injections 1 month apart. If there is incomplete 
      regression of polyps by indocyanine green angiography, eyes should be retreated 
      with verteporfin photodynamic therapy monotherapy or verteporfin photodynamic 
      therapy plus ranibizumab. If there is complete regression of polyps by 
      indocyanine green angiography, but there is leakage on fluorescein angiography 
      and other clinical or anatomical signs of disease activity, eyes should be 
      retreated with ranibizumab. CONCLUSION: Practical guidance on the clinical 
      management of PCV is proposed based on expert evaluation of current evidence.
FAU - Koh, Adrian H C
AU  - Koh AH
AD  - Eye & Retina Surgeons, Camden Medical Centre, Singapore. ahckoh@yahoo.com
CN  - Expert PCV Panel
FAU - Chen, Lee-Jen
AU  - Chen LJ
FAU - Chen, Shih-Jen
AU  - Chen SJ
FAU - Chen, Youxin
AU  - Chen Y
FAU - Giridhar, Anantharam
AU  - Giridhar A
FAU - Iida, Tomohiro
AU  - Iida T
FAU - Kim, Hakyoung
AU  - Kim H
FAU - Yuk Yau Lai, Timothy
AU  - Yuk Yau Lai T
FAU - Lee, Won Ki
AU  - Lee WK
FAU - Li, Xiaoxin
AU  - Li X
FAU - Han Lim, Tock
AU  - Han Lim T
FAU - Ruamviboonsuk, Paisan
AU  - Ruamviboonsuk P
FAU - Sharma, Tarun
AU  - Sharma T
FAU - Tang, Shibo
AU  - Tang S
FAU - Yuzawa, Mitsuko
AU  - Yuzawa M
LA  - eng
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Retina
JT  - Retina (Philadelphia, Pa.)
JID - 8309919
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Coloring Agents)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Porphyrins)
RN  - 0X9PA28K43 (Verteporfin)
RN  - IX6J1063HV (Indocyanine Green)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Choroid/*blood supply
MH  - Choroid Diseases/*diagnosis/*drug therapy
MH  - *Coloring Agents
MH  - Databases, Factual
MH  - Evidence-Based Medicine
MH  - Fluorescein Angiography
MH  - Humans
MH  - Indocyanine Green
MH  - *Photochemotherapy
MH  - Photosensitizing Agents/therapeutic use
MH  - Polyps/*diagnosis/*drug therapy
MH  - Porphyrins/therapeutic use
MH  - Ranibizumab
MH  - Verteporfin
EDAT- 2013/03/05 06:00
MHDA- 2013/10/26 06:00
CRDT- 2013/03/05 06:00
PHST- 2013/03/05 06:00 [entrez]
PHST- 2013/03/05 06:00 [pubmed]
PHST- 2013/10/26 06:00 [medline]
AID - 10.1097/IAE.0b013e3182852446 [doi]
PST - ppublish
SO  - Retina. 2013 Apr;33(4):686-716. doi: 10.1097/IAE.0b013e3182852446.